{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-22-027367","form_type":"8-K/A","ticker":"INBP","cik":"0001016504","company_name":"INTEGRATED BIOPHARMA INC","filed_at":"2022-11-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:49.241585+00:00","generated_at":"2026-06-21T19:14:39.875172+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Integrated BioPharma reports Q1 FY2023 net loss; revenue down 3.1% YoY","bullets":["Revenue $12.3M, down ~3.1% YoY from $12.8M.","Operating income $30K vs $585K; net loss $35K vs net income $516K.","Diluted EPS $0.00 per share vs $0.02 in prior-year quarter.","Co-CEOs cite customer overstocking from pandemic as reason for sales decline.","Two largest customers in Contract Manufacturing segment made up 85% of revenue (91% a year ago)."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-22-027367","json":"https://secwatch.observer/filing/0001437749-22-027367.json","markdown":"https://secwatch.observer/filing/0001437749-22-027367.md","text":"https://secwatch.observer/filing/0001437749-22-027367.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1016504/000143774922027367/0001437749-22-027367-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1016504/000143774922027367/inbp20221114_8ka.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T19:14:39.875172+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"2ce88549132a2ae7bf458f9b0fa16dbbdb435c68","claim":"INTEGRATED BIOPHARMA INC reported quarter ended September 30, 2022 results: revenue $12.3 million, net income net loss of approximately $35,000 or $0.00 per share, EPS $0.00 per share of common stock.","evidence_excerpt":"Inc. (OTCQX: INBP) (the “Company” or “INBP”) reports its financial results for the quarter ended September 30, 2022. Revenue for the quarter ended September 30, 2022 was $12.3 million compared to $12.8 million for the quarter ended September 30, 2021, a decrease of $0.5 million or approximately 3.1%. The Company had operating income for the quarter ended","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1016504/000143774922027367/0001437749-22-027367-index.htm","confidence":0.98,"family_label":"Earnings Releases","details":[{"label":"Period","value":"quarter ended September 30, 2022"},{"label":"Revenue","value":"$12.3 million"},{"label":"Net income","value":"net loss of approximately $35,000 or $0.00 per share"},{"label":"EPS","value":"$0.00 per share of common stock"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}